- Home
- EXEL vs H Comparison
EXEL vs H Comparison
Compare EXEL & H Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- H
- Stock Information
- Founded
- EXEL 1994
- H 1957
- Country
- EXEL United States
- H United States
- Employees
- EXEL N/A
- H N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- H Hotels/Resorts
- Sector
- EXEL Health Care
- H Consumer Discretionary
- Exchange
- EXEL Nasdaq
- H Nasdaq
- Market Cap
- EXEL 11.3B
- H 12.7B
- IPO Year
- EXEL 2000
- H 2009
- Fundamental
- Price
- EXEL $44.08
- H $139.92
- Analyst Decision
- EXEL Buy
- H Buy
- Analyst Count
- EXEL 18
- H 17
- Target Price
- EXEL $43.00
- H $149.41
- AVG Volume (30 Days)
- EXEL 3.3M
- H 987.4K
- Earning Date
- EXEL 08-05-2025
- H 08-07-2025
- Dividend Yield
- EXEL N/A
- H 0.43%
- EPS Growth
- EXEL 237.58
- H 23.10
- EPS
- EXEL 2.20
- H 7.89
- Revenue
- EXEL $2,298,922,000.00
- H $3,216,000,000.00
- Revenue This Year
- EXEL $9.37
- H $111.98
- Revenue Next Year
- EXEL $11.05
- H $5.17
- P/E Ratio
- EXEL $19.98
- H $17.73
- Revenue Growth
- EXEL 24.49
- H N/A
- 52 Week Low
- EXEL $21.82
- H $102.43
- 52 Week High
- EXEL $49.62
- H $168.20
- Technical
- Relative Strength Index (RSI)
- EXEL 57.96
- H 64.63
- Support Level
- EXEL $42.66
- H $127.59
- Resistance Level
- EXEL $49.62
- H $136.53
- Average True Range (ATR)
- EXEL 1.58
- H 3.11
- MACD
- EXEL 0.10
- H 0.18
- Stochastic Oscillator
- EXEL 43.24
- H 86.55
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About H Hyatt Hotels Corporation
Hyatt is an operator of owned (3% of total rooms) and managed and franchised (97%) properties across about 30 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva, and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, the wellness brand Miraval, and the midscale extended-stay brand Studios. Hyatt acquired Two Roads Hospitality in 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 63% Americas, 15% rest of world, and 22% Asia-Pacific.